Alzheimer disease and associated disorders Journal

Overview
Identity
View All

publication venue for

Mapping the Landscape of Those Left Behind When a Person With Dementia Dies: Roles of Race and Ethnicity. 2024
Drivers of Memory Loss Underreport in Mild Cognitive Impairment Due to Alzheimer Versus Vascular Disease.. 38:128-132. 2024
The Technology in Caring Questionnaire: Development and Psychometric Properties.. 38:77-84. 2024
Risk of Neuropsychiatric Symptoms Among People Who Develop Cognitive Impairment With and Without a History of Post-traumatic Stress Disorder.. 38:91-94. 2023
Anticipated Psychological or Behavioral Reactions to Learning Alzheimer Biomarker Results: Associations With Contextual Factors.. 37:282-289. 2023
Remuneration and Recruitment of Study Participants for AD Cohort Studies From the General Public and From Minority Communities.. 37:107-112. 2023
Research Priorities of Individuals and Caregivers With Lewy Body Dementia: A Web-based Survey.. 37:50-58. 2023
Development of a Comprehensive Battery to Collect Social and Structural Determinants of Health (SSDOH) in Cognitively Normal or Very Mildly Impaired Persons.. 36:97-102. 2022
A Novel Method for Establishing Functional Change in Older Adults With Cognitive Impairment.. 36:238-243. 2022
Predictors of Willingness to Enroll in Hypothetical Alzheimer Disease Biomarker Studies that Disclose Personal Results.. 36:125-132. 2022
Beliefs, Understanding, and Barriers Related to Dementia Research Participation Among Older African Americans.. 36:52-57. 2022
Limited Longitudinal Change in Self-reported Spatial Navigation Ability in Preclinical Alzheimer Disease.. 36:15-21. 2022
An Initial Empirical Operationalization of the Earliest Stages of the Alzheimer's Continuum.. 35:62-67. 2021
Biomarker Use for Dementia With Lewy Body Diagnosis: Survey of US Experts.. 35:55-61. 2021
Cerebral Amyloid Angiopathy-related Inflammation Presenting With a Cystic Lesion in Young-onset Alzheimer Disease.. 35:265-268. 2021
Clinical Profiles of Arteriolosclerosis and Alzheimer Disease at Mild Cognitive Impairment and Mild Dementia in a National Neuropathology Cohort.. 35:14-22. 2021
Sex-related Differences in Tau Positron Emission Tomography (PET) and the Effects of Hormone Therapy (HT).. 35:164-168. 2021
Subtle Changes in Medication-taking Are Associated With Incident Mild Cognitive Impairment.. 35:237-243. 2021
Tailoring Research Recruitment for Acute Care Settings: Recommendations from People with Dementia and their Caregivers.. 35:191-199. 2021
Engaging Diverse Older Adults With Cognitive Impairment and Caregivers in Advance Care Planning: A Pilot Study of the Interactive PREPARE Website.. 35:342-349. 2021
Brachial Flow-mediated Dilation and Risk of Dementia: The Cardiovascular Health Study.. 34:272-274. 2020
Comparative Performance and Neuropathologic Validation of the AD8 Dementia Screening Instrument.. 34:112-117. 2020
Dependence Clusters in Alzheimer Disease and Medicare Expenditures: A Longitudinal Analysis From the Predictors Study.. 34:293-298. 2020
Efficacy of Mealtime Interventions for Malnutrition and Oral Intake in Persons With Dementia: A Systematic Review.. 34:366-379. 2020
Expanded Demographic Norms for Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set.. 34:191-197. 2020
Factor Consistency of Neuropsychological Test Battery Versions in the NACC Uniform Data Set.. 34:175-177. 2020
Identifying Adaptive and Maladaptive Behaviors Following a Diagnosis of Mild Cognitive Impairment.. 34:262-266. 2020
Physical Exercise and Longitudinal Trajectories in Alzheimer Disease Biomarkers and Cognitive Functioning.. 34:212-219. 2020
Subjective Memory Complaints Are an Important Surrogate for Objective Cognitive Performance in African Americans.. 34:79-84. 2020
The Utility of the National Alzheimer's Coordinating Center's Database for the Rapid Assessment of Evolving Neuropathologic Conditions.. 34:105-111. 2020
Comment on Andrews et al. 2019
Discriminative Ability of Montreal Cognitive Assessment Subtests and Items in Racial and Ethnic Minority Groups.. 33:226-232. 2019
Reduced Awareness of Memory Deficit is Associated With Increased Medicare Home Health Care Use in Dementia.. 33:62-67. 2019
Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment.. 32:18-27. 2018
Early Midlife Pulmonary Function and Dementia Risk.. 32:270-275. 2018
Medicare Expenditures and Health Care Utilization in a Multiethnic Community-based Population With Dementia From Incidence to Death.. 32:320-325. 2018
Pathologies Underlying Longitudinal Cognitive Decline in the Oldest Old.. 32:265-269. 2018
Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging.. 32:35-42. 2018
Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS).. 32:10-17. 2018
Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals.. 31:69-72. 2017
Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study.. 31:107-113. 2017
Functional Connectivity is Reduced in Early-stage Primary Progressive Aphasia When Atrophy is not Prominent.. 31:101-106. 2017
Increased Reporting Accuracy of Alzheimer Disease Symptoms in Caribbean Hispanic Informants.. 31:328-334. 2017
Neuropsychological Testing in Pathologically Verified Alzheimer Disease and Frontotemporal Dementia: How Well Do the Uniform Data Set Measures Differentiate Between Diseases?. 31:187-191. 2017
The BIOCARD Index: A Summary Measure to Predict Onset of Mild Cognitive Impairment.. 31:114-119. 2017
The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease.. 31:141-145. 2017
Willingness to Be a Brain Donor: A Survey of Research Volunteers From 4 Racial/Ethnic Groups.. 31:135-140. 2017
Anxiety in family caregivers of hospitalized persons with dementia: contributing factors and responses.. 29:236-41. 2015
Does type 2 diabetes increase rate of cognitive decline in older Mexican Americans?. 29:206-12. 2015
Errors in self-reports of health services use: impact on alzheimer disease clinical trial designs.. 29:75-81. 2015
Evaluation of a Brief Survey Instrument for Assessing Subtle Differences in Cognitive Function Among Older Adults.. 29:317-24. 2015
Vascular disease and risk factors are associated with cognitive decline in the alzheimer disease spectrum.. 29:18-25. 2015
Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer's disease.. 28:182-9. 2014
Hospital and nursing home use from 2002 to 2008 among U.S. older adults with cognitive impairment, not dementia in 2002.. 27:372-8. 2013
Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study.. 27:174-81. 2013
Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type.. 26:314-21. 2012
Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer Disease.. 26:17-27. 2012
ApoE E4 is a susceptibility factor in amnestic but not aphasic dementias.. 25:159-63. 2011
Caregiver burden and neuropsychiatric symptoms in older adults with cognitive impairment: the Aging, Demographics, and Memory Study (ADAMS).. 25:116-21. 2011
Microcephaly genes and risk of late-onset Alzheimer disease.. 25:276-82. 2011
Utilization of antihypertensives, antidepressants, antipsychotics, and hormones in Alzheimer disease.. 25:144-8. 2011
A single ascending dose study of bapineuzumab in patients with Alzheimer disease.. 24:198-203. 2010
Evidence of altered posteromedial cortical FMRI activity in subjects at risk for Alzheimer disease.. 24:28-36. 2010
Longitudinal medication usage in Alzheimer disease patients.. 24:354-9. 2010
Computer-based cognitive training for mild cognitive impairment: results from a pilot randomized, controlled trial.. 23:205-10. 2009
Covert processing of words and pictures in nonsemantic variants of primary progressive aphasia.. 22:343-51. 2008
Dementia patient suffering and caregiver depression.. 22:170-6. 2008
Metabolic syndrome and cognitive disorders: is the sum greater than its parts?. 21:167-71. 2007
Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals.. 21:292-9. 2007
3D mapping of mini-mental state examination performance in clinical and preclinical Alzheimer disease.. 20:224-31. 2006
ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trials.. 20:S139-46. 2006
Amyloid-beta immunotherapies in mice and men.. 20:118-23. 2006
Cognitive reserve and Alzheimer disease.. 20:112-7. 2006
Cognitive reserve and Alzheimer disease.. 20:S69-74. 2006
Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging.. 20:77-85. 2006
Alzheimer A beta vaccination of rhesus monkeys (Macaca mulatta).. 18:44-6. 2004
Out-of-pocket health care expenditures among older Americans with dementia.. 18:90-8. 2004
Predicting nursing home admission: estimates from a 7-year follow-up of a nationally representative sample of older Americans.. 18:83-9. 2004
Amyloid-beta binding molecule: potential role in the pathogenesis and treatment of Alzheimer disease.. S66-8. 2003
Evaluation of the diagnosis and management of cognitive impairment in long-term care.. 17:72-6. 2003
Potential role of endogenous and exogenous amyloid-beta binding molecules in the pathogenesis, diagnosis, and treatment of Alzheimer disease.. 17:151-3. 2003
The cognitive syndrome of vascular dementia: implications for clinical trials.. S21-9. 1999